Biological, chemical, and biochemical strategies for modifying glycopeptide antibiotics.

antibiotics chemical biology chemical modification glycopeptide antibiotics glycosylation infectious disease natural product biosynthesis nonribosomal peptide peptide biosynthesis peptide chemical synthesis

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
06 12 2019
Historique:
pubmed: 2 11 2019
medline: 17 6 2020
entrez: 2 11 2019
Statut: ppublish

Résumé

Since the discovery of vancomycin in the 1950s, the glycopeptide antibiotics (GPAs) have been of great interest to the scientific community. These nonribosomally biosynthesized peptides are highly cross-linked, often glycosylated, and inhibit bacterial cell wall assembly by interfering with peptidoglycan synthesis. Interest in glycopeptide antibiotics covers many scientific disciplines, due to their challenging total syntheses, complex biosynthesis pathways, mechanism of action, and high potency. After intense efforts, early enthusiasm has given way to a recognition of the challenges in chemically synthesizing GPAs and of the effort needed to study and modify GPA-producing strains to prepare new GPAs to address the increasing threat of microbial antibiotic resistance. Although the preparation of GPAs, either by modifying the pendant groups such as saccharides or by functionalizing the N- or C-terminal moieties, is readily achievable, the peptide core of these molecules-the GPA aglycone-remains highly challenging to modify. This review aims to present a summary of the results of GPA modification obtained with the three major approaches developed to date:

Identifiants

pubmed: 31672921
pii: S0021-9258(20)30427-0
doi: 10.1074/jbc.REV119.006349
pmc: PMC6901329
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Biological Products 0
Glycopeptides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

18769-18783

Informations de copyright

© 2019 Marschall.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest with the contents of this article.

Références

Curr Opin Struct Biol. 2016 Dec;41:46-53
pubmed: 27289043
Org Lett. 2011 Jul 1;13(13):3438-41
pubmed: 21615166
Nat Chem. 2019 Jan;11(1):78-85
pubmed: 30397320
J Infect Dis. 2008 Apr 15;197(8):1079-81
pubmed: 18419525
Angew Chem Int Ed Engl. 2017 Mar 27;56(14):3770-3821
pubmed: 28323366
ACS Infect Dis. 2016 Sep 9;2(9):642-650
pubmed: 27759388
Bioorg Med Chem Lett. 2002 May 6;12(9):1319-22
pubmed: 11965380
Nature. 2019 Oct;574(7776):86-89
pubmed: 31578481
Curr Opin Chem Biol. 2012 Apr;16(1-2):170-8
pubmed: 22336892
Angew Chem Int Ed Engl. 2001 Dec 17;40(24):4688-4691
pubmed: 12404385
Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9
pubmed: 22431851
J Mol Biol. 2009 Apr 10;387(4):883-98
pubmed: 19340948
Nat Prod Rep. 2015 Aug;32(8):1207-35
pubmed: 25940955
Sci Rep. 2018 Apr 19;8(1):6274
pubmed: 29674657
ACS Synth Biol. 2015 Mar 20;4(3):195-206
pubmed: 23654249
Science. 2006 Sep 1;313(5791):1291-4
pubmed: 16946071
J Antibiot (Tokyo). 1996 Dec;49(12):1236-48
pubmed: 9031670
Chem Biol. 2007 Sep;14(9):1078-89
pubmed: 17884639
J Am Chem Soc. 2016 Jun 1;138(21):6746-53
pubmed: 27213615
J Am Chem Soc. 2012 Apr 11;134(14):6120-3
pubmed: 22462775
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii15-20
pubmed: 15750032
J Am Chem Soc. 2012 Jan 18;134(2):1284-97
pubmed: 22188323
J Antibiot (Tokyo). 1997 Jun;50(6):509-13
pubmed: 9268008
Nat Chem Biol. 2011 May;7(5):304-9
pubmed: 21478878
J Am Chem Soc. 2001 Mar 7;123(9):1862-71
pubmed: 11456806
Chem Commun (Camb). 2018 Feb 22;54(17):2146-2149
pubmed: 29423498
Chembiochem. 2005 Feb;6(2):267-72
pubmed: 15651041
Chem Commun (Camb). 2013 May 18;49(40):4498-500
pubmed: 23571454
J Ind Microbiol Biotechnol. 2018 Jul;45(7):635-649
pubmed: 29288438
Nat Commun. 2019 Jun 13;10(1):2613
pubmed: 31197182
J Org Chem. 2018 Jul 6;83(13):7206-7214
pubmed: 29708747
Angew Chem Int Ed Engl. 2001 May 4;40(9):1693-1696
pubmed: 11353482
Chem Sci. 2018 Oct 10;10(1):118-133
pubmed: 30713624
Chem Sci. 2017 Sep 1;8(9):5992-6004
pubmed: 28989629
J Med Chem. 2009 Mar 12;52(5):1471-6
pubmed: 19209892
ACS Synth Biol. 2014 Oct 17;3(10):748-58
pubmed: 23654258
J Am Chem Soc. 2012 May 30;134(21):8790-3
pubmed: 22568755
Curr Opin Microbiol. 2010 Oct;13(5):595-602
pubmed: 20920883
Mol Biosyst. 2016 Dec 20;13(1):9-22
pubmed: 27853778
Nat Prod Rep. 2018 Aug 15;35(8):757-791
pubmed: 29667657
Curr Top Med Chem. 2017;17(5):620-628
pubmed: 27411322
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4817-9
pubmed: 23880541
Chemistry. 2001 Sep 3;7(17):3798-823
pubmed: 11575782
J Am Chem Soc. 2018 Nov 28;140(47):16140-16151
pubmed: 30388366
Chem Soc Rev. 2012 Feb 7;41(3):957-78
pubmed: 21829829
J Am Chem Soc. 2011 Sep 7;133(35):13946-9
pubmed: 21823662
ACS Chem Biol. 2019 Mar 15;14(3):356-360
pubmed: 30830742
Chem Biol. 2002 Feb;9(2):225-35
pubmed: 11880037
Nature. 2015 May 7;521(7550):105-9
pubmed: 25686610
Antimicrob Agents Chemother. 2009 Nov;53(11):4580-7
pubmed: 19506057
J Med Chem. 2010 Mar 25;53(6):2528-33
pubmed: 20180534
Bioorg Med Chem Lett. 2016 Feb 1;26(3):1025-1028
pubmed: 26725950
Angew Chem Int Ed Engl. 2002 Sep 16;41(18):3383-5
pubmed: 12298039
J Antibiot (Tokyo). 1999 Mar;52(3):319-24
pubmed: 10348049
Angew Chem Int Ed Engl. 2016 Aug 16;55(34):9834-40
pubmed: 27435901
Biochemistry. 2001 Apr 17;40(15):4745-55
pubmed: 11294642
Angew Chem Int Ed Engl. 1998 Oct 16;37(19):2700-2704
pubmed: 29711601
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
pubmed: 20805405
Chem Rev. 2017 Sep 27;117(18):11952-11993
pubmed: 28437097
Lancet. 1988 Jan 2-9;1(8575-6):57-8
pubmed: 2891921
J Am Chem Soc. 2006 Mar 8;128(9):2885-92
pubmed: 16506767
Angew Chem Int Ed Engl. 2015 Dec 21;54(52):15715-9
pubmed: 26549530
J Am Chem Soc. 2013 Aug 21;135(33):12414-21
pubmed: 23924210
J Mol Biol. 2009 Oct 9;392(5):1178-91
pubmed: 19576226
J Am Chem Soc. 2012 Jun 13;134(23):9755-61
pubmed: 22621706
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Nat Biotechnol. 2006 Dec;24(12):1541-50
pubmed: 17160060
Nat Biotechnol. 2013 Oct;31(10):922-7
pubmed: 24056948
Nat Commun. 2018 Jan 2;9(1):22
pubmed: 29295973
Chem Commun (Camb). 2016 Nov 17;52(94):13679-13682
pubmed: 27812569
Nat Biotechnol. 2003 Dec;21(12):1467-9
pubmed: 14608364
J Med Chem. 2013 May 23;56(10):4116-24
pubmed: 23617725
ACS Chem Biol. 2019 Sep 20;14(9):2065-2070
pubmed: 31479234
J Antibiot (Tokyo). 2014 Jan;67(1):31-41
pubmed: 24220108
Nat Rev Drug Discov. 2009 Dec;8(12):929-30
pubmed: 19949399
ACS Infect Dis. 2018 May 11;4(5):715-735
pubmed: 29363950
J Bacteriol. 2004 Sep;186(18):6093-100
pubmed: 15342578
J Am Chem Soc. 2013 Jun 5;135(22):8415-22
pubmed: 23692563
Chem Biol. 2002 Dec;9(12):1305-14
pubmed: 12498883
Angew Chem Int Ed Engl. 2018 Jul 2;57(27):8048-8052
pubmed: 29697176
ACS Chem Biol. 2018 Jan 19;13(1):110-120
pubmed: 29192758
Chembiochem. 2003 Jul 7;4(7):658-62
pubmed: 12851938
J Am Chem Soc. 2004 May 19;126(19):5942-3
pubmed: 15137740
J Antibiot (Tokyo). 1996 Jun;49(6):575-81
pubmed: 8698642
J Med Chem. 2015 Mar 12;58(5):2367-77
pubmed: 25671771
Infect Dis Ther. 2016 Mar;5(1):1-15
pubmed: 26831328
Org Lett. 2019 Nov 1;21(21):8635-8640
pubmed: 31603691

Auteurs

Edward Marschall (E)

The Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia; EMBL Australia, Monash University, Clayton, Victoria 3800, Australia.

Max J Cryle (MJ)

The Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia; EMBL Australia, Monash University, Clayton, Victoria 3800, Australia. Electronic address: max.cryle@monash.edu.

Julien Tailhades (J)

The Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia; EMBL Australia, Monash University, Clayton, Victoria 3800, Australia. Electronic address: julien.tailhades@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH